P1134: OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA POST-CBTK INHIBITOR THERAPY IN THE UNITED STATES AND JAPAN: A STUDY OF TWO REAL-WORLD DATABASES

• S. Rai,
• L. Hess,
• Y. Chen,
• P. Abada,
• H. Konig,
• R. Walgren,
• Y. Tanizawa,
• Z. Cai,
• M. Tajimi

Affiliations

S. Rai

1 Kindai University Faculty of Medicine, Osakasayama, Japan

L. Hess

2 Eli Lilly and Company, Indianapolis, United States of America

Y. Chen

2 Eli Lilly and Company, Indianapolis, United States of America

P. Abada

2 Eli Lilly and Company, Indianapolis, United States of America

H. Konig

2 Eli Lilly and Company, Indianapolis, United States of America

R. Walgren

2 Eli Lilly and Company, Indianapolis, United States of America

Y. Tanizawa

3 Eli Lilly Japan K.K, Kobe, Japan

Z. Cai

3 Eli Lilly Japan K.K, Kobe, Japan

M. Tajimi

3 Eli Lilly Japan K.K, Kobe, Japan